Trevi Therapeutics Return on Equity

Trevi Therapeutics (TRVI) currently reports a ROE of -20.07%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore Trevi Therapeutics's ROE history and peer comparisons.

Trevi Therapeutics's ROE of -20.07% is lower than the Healthcare sector average of 13.26%. That is roughly 251.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Trevi Therapeutics's current -20.07% should be judged against Healthcare norms (sector average: 13.26%) and against TRVI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -20.07%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Trevi Therapeutics, and consider following TRVI for alerts when major investors trade the stock.

Trevi Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -20.07% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRVI with unrelated industries.